Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex improves muscle function after standard neuromuscular recovery (SIMAR)
2009-017085-22Phase 4Completed
- Sponsor
- Technical University of Munich
- Start
- Mar 2010
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of Sugammadex in neuromuscular block (NMB), sponsored by Technical University of Munich. Primary endpoint: Reduction of postoperative muscle weakness. Started Mar 2010; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2009-017085-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017085-22.